2026-04-14T06:56:05Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1986662025-12-05T12:04:41Zcom_2072_1057col_2072_478916col_2072_478917

00925njm 22002777a 4500 dc Pignata, Sandro author Oza, Amit M. author Hall, Geoff author Pardo, Beatriz author Madry, Radoslaw author Cibula, David author Klat, Jaroslav author Montes Worboys, Ana author Glasspool, Rosalind author Colombo, Nicoletta author Pete, Imre author Herrero Ibáñez, Ana author Romeo Marín, Margarita author Ilieva, Rumyana author Timcheva, Constanta author Maio, Massimo di author Blakeley, Christopher author Taylor, Rosie author Barnicle, Alan author Clamp, Andrew author 2023-05-30T08:31:34Z 2023-05-30T08:31:34Z 2023-05-01 2023-05-29T12:15:04Z Background. The open-label, single-arm, multicenter ORZORA trial (NCT02476968) evaluated the efficacy and safety of maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer (PSR OC) who had tumor BRCA mutations (BRCAm) of germline (g) or somatic (s) origin or non-BRCA homologous recombination repair mutations (HRRm) and were in response to their most recent platinum-based chemotherapy after >= 2 lines of treatment. Methods. Patients received maintenance olaparib capsules (400 mg twice daily) until disease progression. Prospective central testing at screening determined tumor BRCAm status and subsequent testing determined gBRCAm or sBRCAm status. Patients with predefined non-BRCA HRRm were assigned to an exploratory cohort. Càncer d'ovari Genètica Ovarian cancer Genetics Maintenance olaparib in patients with platinum-sensitive relapsed ovarian cancer: Outcomes by somatic and germline BRCA and other homologous recombination repair gene mutation status in the ORZORA trial